Trial Profile

A phase Ib/IIa pilot trial of the oral Hedgehog Signalling Inhibitor, Glasdegib, in Patients with sclerotic chronic graft-versus-host disease refractory to second-line treatment

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 05 Mar 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Glasdegib (Primary)
Indications Graft-versus-host disease
Focus Adverse reactions
Acronyms GETH trial

Most Recent Events

13 Dec 2022 Results from two clinical studies: NCT03415867 and NCT04111497 assessing safety and efficacy of glasdegib in adult patients with refractory scGVHD at data cutoff of 12-months presented at the 64th American Society of Hematology Annual Meeting and Exposition
21 Nov 2021 Status changed from active, no longer recruiting to completed.
17 Jun 2021 Results presented at the 26th Congress of the European Haematology Association

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial